RGD Reference Report - Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.

Authors: Ahn, HS  Chackalamannil, S  Boykow, G  Graziano, MP  Foster, C 
Citation: Ahn HS, etal., Curr Pharm Des. 2003;9(28):2349-65.
RGD ID: 1581036
Pubmed: PMID:14529396   (View Abstract at PubMed)

Thrombin, a plasma serine protease, plays a key role not only in coagulation and hemostasis but in thrombosis, restenosis and atherosclerosis. Thrombin activates platelets, endothelium, inflammatory cells and smooth muscle cells. The cellular action of thrombin is mediated by specific G-protein coupled thrombin receptors called proteinase-activated receptors (protease-activated receptor or PARs). Among the three thrombin receptors, PAR1 is the primary thrombin receptor in human and animal cells with an exception of non-primate platelets. An increased thrombin generation and PAR1 expression are observed on cells within atherosclerotic plaque and thrombus and following vascular injury. Animal studies with PAR1 deficient mice and small molecule antagonists indicate an important role of PAR1 in thrombosis and restenosis and thus the therapeutic potential of a PAR1 antagonist in treating these diseases. Development of a thrombin receptor tethered ligand analog binding assay led to the discovery of several different series of potent, nonpeptide small molecular antagonists of PAR1. These antagonists are PAR1 selective and inhibit most of the cellular effects of thrombin. A PAR1 antagonist has an advantage over a direct thrombin inhibitor since it does not inhibit enzymatic action of thrombin in the coagulation cascade with the consequent minimal bleeding side-effects, unlike a direct thrombin inhibitor. In addition, the emerging evidence for the role of PAR1 in various inflammatory diseases suggests as yet unexplored therapeutic potentials of PAR1 antagonists in various inflammatory diseases.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
coronary restenosis  ISOF2r (Mus musculus)1581036; 1581036 RGD 
coronary restenosis  TAS 1581036 RGD 
thrombosis  ISOF2r (Mus musculus)1581036; 1581036 RGD 
thrombosis  TAS 1581036 RGD 

Objects Annotated

Genes (Rattus norvegicus)
F2r  (coagulation factor II (thrombin) receptor)

Genes (Mus musculus)
F2r  (coagulation factor II thrombin receptor)

Genes (Homo sapiens)
F2R  (coagulation factor II thrombin receptor)


Additional Information